Physician profile
Sergei Belenky
NPI 1750373171
$774,645.27
in general payments reported to CMS, 2019-2025
46 companies · $121K in 2025
The $121K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147K · 2020: $62K · 2021: $78K · 2022: $131K · 2023: $152K · 2024: $84K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $294K · Travel and Lodging: $32K · Food and Beverage: $21K · Consulting Fee: $9,662 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $294,041.65 |
| Travel and Lodging | $31,588.83 |
| Food and Beverage | $21,362.40 |
| Consulting Fee | $9,661.50 |
| Education | $116.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $240,796.78 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $226,205.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $157,030.17 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $40,401.52 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genentech USA, INC. | $24,994.89 | 2019-2025 | Xolair |
| Pfizer INC. | $18,370.23 | 2019-2024 | |
| Shire North American Group INC | $11,889.88 | 2019 | |
| Csl Behring | $9,283.45 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $8,837.44 | 2020-2025 | Eohilia |
| Grifols USA, LLC | $8,291.72 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,143.10 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $5,574.51 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $3,960.83 | 2019-2025 | Xolair |
| Amgen INC. | $3,058.30 | 2022-2025 | Tezspire |
| Kaleo, INC. | $2,456.60 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,894.92 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $1,089.25 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $643.90 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $628.20 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $594.28 | 2019-2025 | Ruconest |
| Optinose US, INC. | $338.56 | 2019-2022 | |
| Abbvie INC. | $289.06 | 2021-2023 | Rinvoq |
| Sanofi-Aventis U.S. LLC | $240.02 | 2021-2024 | |
| Alk-Abello, INC | $194.94 | 2019-2021 | |
| Horizon Therapeutics Plc | $163.93 | 2019-2021 | |
| Lilly USA, LLC | $145.60 | 2024-2025 | Ebglyss |
| Incyte Corporation | $135.65 | 2024-2025 | Opzelura |
| Merck Sharp & Dohme LLC | $124.39 | 2023 | |
| Genentech, INC. | $123.50 | 2024 | |
| Galderma Laboratories, L.P. | $96.06 | 2025 | Nemluvio |
| Phadia US INC. | $92.57 | 2024 | Immunocap |
| Verona Pharma, INC. | $90.00 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $59.40 | 2025 | Dawnzera, Donidalorsen |
| Mylan Specialty L.P. | $54.58 | 2019-2024 | Yupelri |
| Azurity Pharmaceuticals, INC. | $50.88 | 2025 | Alvesco |
| Vifor Pharma, INC. | $49.37 | 2025 | Zemaira |
| Organon LLC | $43.28 | 2025 | Vtama |
| Sunovion Pharmaceuticals INC. | $28.91 | 2019 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Leo Pharma INC. | $26.84 | 2022 | |
| Invivyd INC | $25.05 | 2025 | Pemgarda |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.96 | 2019 | |
| Gc Biopharma USA, INC. | $23.44 | 2025 | Alyglo |
| Hikma Pharmaceuticals USA | $22.39 | 2024 | Ryaltris |
| Circassia INC. | $17.02 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergei Belenky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.